We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Collaboration and Licensing Agreement Expanded to Exploit Isoforms as Diagnostic Markers

By LabMedica International staff writers
Posted on 07 May 2012
Print article
Pressure BioSciences, Inc (PBI; South Eastern, MA, USA) and Target Discovery, Inc. (TDI; Palo Alto, California, USA) are expanding their strategic license agreement and collaboration in support of TDI's planned offering of personalized medicine, clinical diagnostic services. The nonexclusive, worldwide, royalty-bearing license is for the in vitro diagnostic services testing for the detection of proteins that may be regarded as biomarkers of ovarian and other cancers, including any number of specific or all protein isoforms.

The signing of the expanded strategic technology license and supply agreements give TDI the right to use PBI's Pressure Cycling Technology (PCT) platform for their planned entry into the clinical diagnostics testing market.

The planned commercial diagnostic services will initially target critical needs in treatment selection guidance for ovarian cancer. Until now, PBI's PCT platform has been available for research use only.

The original collaboration between the two companies enabled combination of PBI's PCT Platform with TDI's proprietary reagents for the extraction of membrane protein biomarkers from human tissue. Such biomarkers include specific modified proteins (isoforms) that were previously very difficult to extract from tissue in a form suitable for diagnostic testing. The companies believe that the ability to rapidly extract and recover diagnostically and commercially useable protein isoforms from cell membranes is unique to PCT and the TDI reagents, and that this capability positions the companies to exploit this critical class of membrane proteins as diagnostic biomarkers.

"Membrane proteins play key biological roles in cancer, in drug resistance, and in viral infections, yet until now scientists have been virtually unable to use this important class of biomarkers for diagnostic and prognostic testing," commented Dr. Luke V. Schneider, TDI's CSO. "These proteins are tightly bound within the cell membrane, making them very difficult to extract and recover for scientific study. The extraction of membrane proteins from tissue samples typically requires the use of aggressive physical and chemical methods that yield useless protein fragments, often in solutions that are completely incompatible for laboratory testing. Consequently, although membrane proteins and their isoforms play vital roles in human health and disease, they have never been conveniently available for use as disease biomarkers."

Target Discovery, Inc., develops the next generation of clinical diagnostics, offering higher-value molecular insights for disease management and diagnosis. The company focuses on creating protein isoform diagnostics to better guide therapeutic choices and lower overall treatment costs for cancer and other diseases.

Pressure BioSciences, Inc. is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on PCT. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems for mass spectrometry, biomarker discovery, biotherapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Related Links:

Pressure BioSciences, Inc.
Target Discovery, Inc


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.